1 May 2019 in Veterinary Immunology and Immunopathology
1 March 2015 in Transplantation Direct
Background CD28 signal blockade after T cell receptor activation is under intense investigation as a tolerance-inducing therapy for transplantation. Our goal is to produce a CD28-specific reagent as a therapy for the prevention of graft rejection and graft-versus-host disease in the canine model of allogeneic hematopoietic cell transplantation. Methods We infused a monoclonal mouse anticanine CD28 antibody (1C6 mAb) into 4 dogs and a fragment of antigen-binding (1C6 Fab) into 2 dogs. Pharmacokinetics, pathology, cytokine release, and the crystal structure of 1C6 Fv were evaluated. Results Within an hour of an intravenous injection of the 1C6 mAb, the dogs became leukopenic and developed a steroid-refractory cytokine storm. Two of the dogs developed high fevers, one experienced diffuse alveolar hemorrhage and another developed gastrointestinal hemorrhage. The cytokine storm was characterized by elevated plasma levels of monocyte chemotactic protein-1, interferon gamma inducible protein-10, interleukin (IL)-10, IL-6, and tumor necrosis factor-α. In addition, 1 dog showed elevated levels of IL-2, IL-8, and IL-18. In contrast, infusion of 1C6 Fab was well tolerated without any side effects. Dry-coating 1C6 mAb onto tissue culture plates induced CD3-independent proliferation and tumor necrosis factor-α production. Crystal structure analysis revealed that 1C6 binds to canine CD28 in a manner different than previously reported for conventional agonistic or superagonistic antibodies. Conclusions These results indicate that dogs and humans develop a similar cytokine storm after infusion of anti-CD28 mAb, providing an appropriate large animal for further study. The 1C6 Fab warrants evaluation as a tolerance-inducing reagent in the canine model of allogeneic hematopoietic cell transplantation.
1 January 2018 in Transplantation and Cellular Therapy
In murine model systems inducible costimulator (ICOS) signaling has been implicated in the formation of chronic graft-versus-host disease (GVHD). Previously, we showed that chronic GVHD can be reproducibly produced in the dog hematopoietic cell transplantation (HCT) model and that ICOS expression is upregulated on T cells in dogs with chronic GVHD. The goal of the present study was to determine whether administration of a short course of anti-canine ICOS mAb could alter the rapid and progressive course of chronic GVHD. Five dogs underwent HCT from dog leukocyte antigen mismatched unrelated donors after total body irradiation. Postgrafting immunosuppression consisted of methotrexate (days 1, 3, 6, and 11) and cyclosporine (days -1 through 78). Anti-ICOS mAb (3 injections, 72 hours apart) was administered upon diagnosis of GVHD. One dog failed to respond to anti-ICOS mAb therapy and succumbed to chronic GVHD in a time course similar to control untreated dogs. Overall, anti-ICOS-treated dogs experienced a significant prolongation in survival from the time of diagnosis of chronic GVHD compared with control dogs. Within the limitations of the number of study dogs we suggest that a short course of anti-ICOS mAb may be useful in the treatment of chronic canine GVHD.